Clinical development of asciminib (ABL001): A randomized phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia (CML) Meeting Abstract
| Authors: | Mauro, M. J.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Hochhaus, A.; Minami, H.; Boquimpani, C.; Minami, Y.; Breccia, M.; Goh, Y. T.; Ottmann, O.; Sondhi, M.; Hois, S.; Bédoucha, V.; Perraud, K.; Rea, D.; DeAngelo, D. J. |
| Abstract Title: | Clinical development of asciminib (ABL001): A randomized phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia (CML) |
| Meeting Title: | 6th Annual Meeting of the Society of Hematologic Oncology (SOHO 2018) |
| Keywords: | inhibitor; chronic myeloid leukemia; tyrosine kinase; bosutinib; asciminib; abl001 |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 18 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Sep 12-15 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-09-01 |
| Start Page: | S223 |
| Language: | English |
| ACCESSION: | WOS:000444343400144 |
| DOI: | 10.1016/j.clml.2018.07.094 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CML-063 -- Source: Wos |
